This study, conducted within the framework of the MMVision mono-institutional observational program, aims to explore inflammatory and immune-related mechanisms associated with thrombotic events in MM patients treated with IMiD- and anti-CD38-based regimens. The gene discussed is CD38; the disease is Miyoshi myopathy.